Drug intelligence / Profile preview

CTA002

Development stage: Preclinical
Lead developer: CTCELLS
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CTA002 (also known as CTA-02) is an early-stage programmed death-ligand 1 (PD-L1) inhibitor being developed by CTCELLS. It is currently in the discovery phase for the treatment of various neoplasms, as well as skin and musculoskeletal conditions. As a checkpoint inhibitor, CTA002 is designed to block the interaction between PD-L1, often expressed on the surface of tumor cells, and the PD-1 receptor on T cells. By inhibiting this pathway, the drug aims to prevent immune evasion by tumors and restore the ability of the immune system to recognize and eliminate malignant cells.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on CTA002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTA002.

Explore the full profile